Literature DB >> 12111704

Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.

Georg Schatzl1, Stephan Madersbacher, Andrea Gsur, Martin Preyer, Gerald Haidinger, Andrea Haitel, Christian Vutuc, Michael Micksche, Michael Marberger.   

Abstract

BACKGROUND: The aim of this study was to assess the impact of polymorphisms of three genes within the androgen pathway on prostate volume, clinical parameters, and endocrine status.
METHODS: Elderly men with lower urinary tract symptoms underwent clinical and endocrine work-up. In parallel, polymorphisms within the 5alpha-reductase gene (SRD5A2 V89L and A49T), the androgen receptor gene (AR; number of CAG repeats), and the prostate specific antigen (PSA) gene (A --> G substitution at position-158) were determined by polymerase chain reaction and restriction-length polymorphism analysis by using DNA from peripheral blood.
RESULTS: A total of 190 men (66.5 +/- 9.2 yr) were analyzed. The number of CAG repeats within the AR and the PSA polymorphism revealed no associations to clinical and endocrine parameters. Individuals carrying the mutated SRD5A2 A49T allele (5.3% of the total population) had larger prostates (54.1 vs. 39.3 ml), higher PSA levels (12.2 vs. 4.3 ng/ml), and a 35% reduction in prostatic stroma/epithelial cell ratio. Men with the mutated SRD5A2 V89L gene had lower testosterone levels.
CONCLUSIONS: In contrast to prostate cancer, polymorphisms within AR and PSA genes do not seem to be of importance for benign prostatic hyperplasia. Polymorphisms within the 5alpha-reductase gene are interesting biomarkers for the development of benign prostatic hyperplasia and benign prostatic enlargement. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111704     DOI: 10.1002/pros.10101

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.

Authors:  C Leigh Pearce; David J Van Den Berg; Nick Makridakis; Juergen K V Reichardt; Ronald K Ross; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson
Journal:  Hum Mol Genet       Date:  2008-05-10       Impact factor: 6.150

Review 2.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

3.  The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.

Authors:  Gerald L Andriole; Christie McCullum-Hill; Gurdarshan S Sandhu; E David Crawford; Michael J Barry; Alan Cantor
Journal:  J Urol       Date:  2012-12-14       Impact factor: 7.450

4.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Authors:  Alan R Kristal; Douglas K Price; Cathee Till; Jeannette M Schenk; Marian L Neuhouser; Sandy Ockers; Daniel W Lin; Ian M Thompson; William D Figg
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

5.  Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?

Authors:  Jeannette M Schenk; Rachel Hunter-Merrill; Yingye Zheng; Ruth Etzioni; Roman Gulati; Catherine Tangen; Ian M Thompson; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2013-06-28       Impact factor: 4.897

6.  Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.

Authors:  Nishit K Mukhopadhyay; Jayoung Kim; Bekir Cinar; Aruna Ramachandran; Martin H Hager; Dolores Di Vizio; Rosalyn M Adam; Mark A Rubin; Pradip Raychaudhuri; Arrigo De Benedetti; Michael R Freeman
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

Review 7.  Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Authors:  Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

8.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

9.  Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.

Authors:  Richard Berges; Andrea Gsur; Elisabeth Feik; Klaus Höfner; Theodor Senge; Ludger Pientka; Andreas Baierl; Martin C Michel; Anton Ponholzer; Stephan Madersbacher
Journal:  World J Urol       Date:  2009-11-17       Impact factor: 4.226

10.  Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture.

Authors:  Shabnam Ziaee; Leland W K Chung
Journal:  Mol Cancer       Date:  2014-09-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.